| 0.3325 0.014 (4.3%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.45  |
1-year : | 0.51 |
| Resists | First : | 0.39 |
Second : | 0.44 |
| Pivot price | 0.36 |
|||
| Supports | First : | 0.31 | Second : | 0.25 |
| MAs | MA(5) : | 0.33 |
MA(20) : | 0.36 |
| MA(100) : | 0.31  |
MA(250) : | 0.51 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.3 |
D(3) : | 17.3 |
| RSI | RSI(14): 44.7 |
|||
| 52-week | High : | 1.26 | Low : | 0.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CODX ] has closed above bottom band by 19.4%. Bollinger Bands are 11.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.35 - 0.35 | 0.35 - 0.35 |
| Low: | 0.31 - 0.31 | 0.31 - 0.31 |
| Close: | 0.31 - 0.32 | 0.32 - 0.32 |
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Wed, 22 Oct 2025
Co-Dx (Nasdaq: CODX) to showcase PCR platform at Global Health Exhibition 2025 - Stock Titan
Wed, 22 Oct 2025
Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia - PR Newswire
Thu, 16 Oct 2025
D. Boral Capital Maintains Co-Diagnostics (CODX) Buy Recommendation - Nasdaq
Thu, 16 Oct 2025
30K primary health centers: Co-Diagnostics develops low-cost sample prep instrument for PCR in India - Stock Titan
Mon, 13 Oct 2025
Oct 22-23: Co-Diagnostics Joins 2025 Maxim Growth Summit, Holding One-on-One Investor Meetings - Stock Titan
Mon, 13 Oct 2025
Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 3.642e+007 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 1,360 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.747e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 946.1 % |
| Return on Equity (ttm) | -38.1 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | -99.9 |
| Sales Per Share | -67.45 |
| EBITDA (p.s.) | 422862 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.27 |
| Dividend | 0 |
| Forward Dividend | 440570 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|